Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

de Castro Carpeño,Javier; Gascón-Vilaplana,Pere; Casas‑Fernández‑de Tejerina,Ana  Maria; Antón‑Torres,Antonio; López‑López,Rafael; Barnadas‑Molins,Agustí; Cruz‑Hernández,Juan  Jesús; Massuti‑Sureda,Bartomeu; Camps‑Herrero,Carlos; Aranda‑Aguilar,Enrique; Rebollo Laserna,Francisco  José

doi:10.3892/mco.2015.524

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

Authors:
- Javier de Castro Carpeño
- Pere Gascón-Vilaplana
- Ana Maria Casas‑Fernández‑de Tejerina
- Antonio Antón‑Torres
- Rafael López‑López
- Agustí Barnadas‑Molins
- Juan Jesús Cruz‑Hernández
- Bartomeu Massuti‑Sureda
- Carlos Camps‑Herrero
- Enrique Aranda‑Aguilar
- Francisco José Rebollo Laserna
View Affiliations

Affiliations: University Hospital La Paz, 28046 Madrid, Spain, Hospital Clinic of Barcelona, 08036 Barcelona, Spain, University Hospital Virgen del Rocío, 41013 Seville, Spain, University Hospital Miguel Servet, 50009 Zaragoza, Spain, University Hospital Complex of Santiago, 15706 Santiago de Compostela, Spain, Department of Medical Oncology, Hospital of Saint Paul, 08025 Barcelona, Spain, University Hospital of Salamanca, 37007 Salamanca, Spain, University General Hospital of Alicante, 03010 Alicante, Spain, University General Hospital of Valencia, University of Valencia, 46014 Valencia, Spain, Maimónides Institute of Biomedical Research, Hospital Reina Sofía, University of Córdoba, 14004 Cordoba, Spain, Sandoz Farmacéutica SA, 28023 Madrid, Spain
Published online on: March 5, 2015 https://doi.org/10.3892/mco.2015.524
Pages: 725-729

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Febrile neutropenia (FN) is one of the most common adverse events associated with myelosuppressive chemotherapy for cancer treatment. The objective of this study was to describe the incidence of hospitalization due to FN in Spanish tertiary care hospitals (PINNACLE study). This epidemiological, retrospective, multicenter, nationwide study involved 119 patients from oncology units of 10 Spanish tertiary care hospitals who were admitted for FN. The primary endpoint was to assess the epidemiology and characteristics of FN. The incidence of admissions due to FN in oncology patients was 2.0% (interquartile range [IQR], 1.6‑3.0). In terms of fever and absolute neutrophil count (ANC), 37.0% of the patients had a temperature of ≥38.2˚C and an ANC of ≤500/m3. The number of patients who received prophylactic treatment with granulocyte colony‑stimulating factor (G‑CSF) was significantly higher in the palliative group (32.6%) compared with that in the non‑palliative group (13.5%). The hospital length of stay was significantly shorter in patients who received prophylactic G‑CSF compared with those who did not (5.0 days; IQR, 4.0‑9.0 vs. 7.0 days; IQR, 5.0‑11.0, respectively). The hospital length of stay was also significantly shorter in patients receiving palliative treatment (5.0 days; IQR, 3.0‑7.0) compared with those receiving non‑palliative therapy (7.0 days; IQR, 5.0‑12.0). In conclusion, the incidence of admissions due to FN in oncology patients was 2.0% and the duration of hospital stay was 7.0 days. Prophylactic G‑CSF treatment was found to be associated with better outcomes and shorter hospital stays. therefore, the use of this treatment becomes relevant for achieving better clinical outcomes and reducing hospitalization cost in the management of FN.

View Figures

View References

1	Caggiano V, Weiss RV, Rickert TS and Linde-Zwirble WT: Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 103:1916–1924. 2005. View Article : Google Scholar : PubMed/NCBI
2	de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH and Roila F: ESMO Guidelines Working Group: Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 21:(Suppl 5). v252–v256. 2010. View Article : Google Scholar : PubMed/NCBI
3	Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV and Fox KR: First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol. 16:2392–2400. 1998.PubMed/NCBI
4	Klastersky J: Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 39:(Suppl 1). S32–S37. 2004. View Article : Google Scholar : PubMed/NCBI
5	Kuderer NM, Dale DC, Crawford J, Cosler LE and Lyman GH: Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer. 106:2258–2266. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 34:730–751. 2002. View Article : Google Scholar : PubMed/NCBI
7	Talcott JA, Finberg R, Mayer RJ and Goldman L: The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 148:2561–2568. 1988. View Article : Google Scholar : PubMed/NCBI
8	Gala Peralta S, Cardesa Salzman T, García García JJ, Estella Aguado J, Gené Giralt A and Luaces Cubells C: Bacteraemia risk criteria in the paediatric febrile neutropenic cancer patient. Clin Transl Oncol. 7:165–168. 2005.(In Spanish). View Article : Google Scholar : PubMed/NCBI
9	Cairo MS: Dose reductions and delays: Limitations of myelosuppressive chemotherapy. Oncology (Williston Park). 14:(Suppl 8). 21–31. 2000.PubMed/NCBI
10	Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L and Valagussa P: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ. 330:217–222. 2005. View Article : Google Scholar : PubMed/NCBI
11	Chang J: Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 36:(Suppl 1). S11–S14. 2000. View Article : Google Scholar : PubMed/NCBI
12	Lyman GH, Dale DC and Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 21:4524–4531. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS and Yu J: Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 116:5555–5563. 2010. View Article : Google Scholar : PubMed/NCBI
14	García-Carbonero R, Mayordomo JI, Tornamira MV, et al: Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst. 93:31–38. 2001. View Article : Google Scholar : PubMed/NCBI
15	Gómez Raposo C, Pinto Marín A and González Barón M: Colony-stimulating factors: Clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol. 8:729–734. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kuderer NM, Dale DC, Crawford J and Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol. 25:3158–3167. 2007. View Article : Google Scholar : PubMed/NCBI
17	Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
18	Aapro MS, Bohlius J, Cameron DA, et al: European Organisation for Research and Treatment of Cancer: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
19	Carrato A, Paz-Ares Rodríguez L, Rodríguez Lescure A, et al: Spanish Society of Medical Oncology (SEOM): Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. Clin Transl Oncol. 11:446–454. 2009. View Article : Google Scholar : PubMed/NCBI
20	Jolis L, Carabantes F, Pernas S, Cantos B, López A, Torres P, Funes C, Caballero D, Benedit P and Salar A: PRAXIS Study Group: Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: A prospective, observational study. Eur J Cancer Care (Engl). 22:513–521. 2013. View Article : Google Scholar : PubMed/NCBI
21	Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 18:3038–3051. 2000.PubMed/NCBI
22	Lyman GH, Lyman CH and Agboola O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 10:427–437. 2005. View Article : Google Scholar : PubMed/NCBI
23	Innes H and Marshall E: Outpatient therapy for febrile neutropenia. Curr Opin Oncol. 19:294–298. 2007.PubMed/NCBI
24	Flowers CR, Seidenfeld J, Bow EJ, et al: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 31:794–810. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lathia N, Mittmann N, DeAngelis C, Knowles S, Cheung M, Piliotis E, Shear N and Walker S: Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 116:742–748. 2010. View Article : Google Scholar : PubMed/NCBI
26	Saloustros E, Tryfonidis K and Georgoulias V: Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother. 12:851–863. 2011. View Article : Google Scholar : PubMed/NCBI
27	Clark OA, Lyman GH, Castro AA, Clark LG and Djulbegovic B: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol. 23:4198–4214. 2005. View Article : Google Scholar : PubMed/NCBI
28	Wong GC and Tan BH: Use of antibiotics in a haematology ward - an audit. Ann Acad Med Singapore. 37:21–26. 2008.PubMed/NCBI
29	Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim R, Tambyah PA and Hsu LY: Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore. 39:453–459. 2010.PubMed/NCBI